Market capitalization | $2.78m |
Enterprise Value | $-7.53m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.85 |
P/B ratio (TTM) P/B ratio | 0.51 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-9.39m |
Free Cash Flow (TTM) Free Cash Flow | $-8.90m |
Cash position | $10.31m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
2 Analysts have issued a Cellect Biotechnology Ltd Sponsored ADR forecast:
2 Analysts have issued a Cellect Biotechnology Ltd Sponsored ADR forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.10 -0.10 |
0%
0%
|
|
EBITDA | -9.29 -9.29 |
2%
2%
|
EBIT (Operating Income) EBIT | -9.39 -9.39 |
2%
2%
|
Net Profit | -8.75 -8.75 |
2%
2%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Cellect Biotechnology Ltd. engages in the provision of regenerative medicine. Its activities include development of regenerative medicine through the development of products facilitating immune stem cell selection. The company also develops innovative technology, which allows the default stem cells by dramatically reducing of complications existing in conventional selection methods. The company was founded by Kasbian Nuriel Chirich, Shai Yarkoni, and Nadir Askenasy on August 4, 1986 and is headquartered in Kfar Saba, Israel.
Head office | Israel |
CEO | Michael Myers |
Employees | 4 |
Founded | 2018 |
Website | www.quoinpharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.